• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强替代终点生物标志物的效能:预测因素的整合

Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.

作者信息

Burke H B

机构信息

University of Nevada School of Medicine, Washoe Medical Center, Reno 89520.

出版信息

J Cell Biochem Suppl. 1994;19:278-82.

PMID:7823601
Abstract

A variable that predicts an outcome with sufficient accuracy is called a predictive factor. Predictive factors can be divided into three types based on the outcomes to be predicted and on the accuracy with which they can be predicted. These three types include risk factors, where the main outcome of interest is incidence and the predictive accuracy is less than 100%; diagnostic factors, where the main outcome of interest is also incidence but the predictive accuracy is almost 100%; and prognostic factors, where the main outcome of interest is death and the predictive accuracy is variable. Surrogate outcomes are predictive factors that are used for a purpose beyond the prediction of an outcome--surrogate outcomes are predictive factors that are substituted for the true outcome in order to determine the effectiveness of an intervention. Surrogate outcomes used in clinical trials are called intermediate endpoints and surrogate endpoints. Predictive factors used as surrogate outcomes have a poor accuracy rate in predicting the true outcome; aggregating risk factors increases predictive accuracy. Artificial neural networks effectively combine predictive factors. Aggregating predictive factors increases the degree of linkage of the surrogate outcome to the true outcome. The resulting increase in predictive accuracy allows enrollment of people most likely to benefit from intervention. This increases the trial's efficiency, reducing the number of people required to assess a chemopreventive agent.

摘要

能够以足够的准确性预测结果的变量称为预测因素。根据要预测的结果以及预测的准确性,预测因素可分为三种类型。这三种类型包括风险因素,其关注的主要结果是发病率且预测准确性低于100%;诊断因素,其关注的主要结果也是发病率但预测准确性几乎为100%;以及预后因素,其关注的主要结果是死亡且预测准确性各不相同。替代结局是用于预测结果之外目的的预测因素——替代结局是为确定干预措施的有效性而替代真实结局的预测因素。临床试验中使用的替代结局称为中间终点和替代终点。用作替代结局的预测因素在预测真实结局方面准确率较低;汇总风险因素可提高预测准确性。人工神经网络有效地组合预测因素。汇总预测因素可增加替代结局与真实结局的关联程度。由此提高的预测准确性使得能够招募最有可能从干预中受益的人群。这提高了试验效率,减少了评估化学预防剂所需的人数。

相似文献

1
Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.增强替代终点生物标志物的效能:预测因素的整合
J Cell Biochem Suppl. 1994;19:278-82.
2
Risk biomarkers and current strategies for cancer chemoprevention.癌症化学预防的风险生物标志物及当前策略。
J Cell Biochem Suppl. 1996;25:1-14.
3
Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.用于II期癌症化学预防试验的替代终点生物标志物。
J Cell Biochem Suppl. 1994;19:1-9.
4
Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.用于大规模化学预防试验的队列选择的癌症风险因素。
J Cell Biochem Suppl. 1996;25:29-36.
5
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.观点:替代终点生物标志物在开发针对散发性癌症的癌症化学预防药物方面的作用可能有限。
Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):589-92.
6
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.反驳观点:由于一些替代终点生物标志物可测量肿瘤形成过程,因此它们在开发针对散发性癌症的癌症化学预防剂方面将具有很高的实用性。
Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6.
7
Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.与证明化学预防剂的安全性和有效性相关的方案设计考量。
J Cell Biochem Suppl. 1997;27:1-6.
8
Does the Prentice criterion validate surrogate endpoints?普伦蒂斯标准是否验证了替代终点?
Stat Med. 2004 May 30;23(10):1571-8. doi: 10.1002/sim.1780.
9
A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.乳腺癌化学预防中生物标志物作为替代终点适用性的清单。
J Cell Biochem Suppl. 1994;19:173-85.
10
Statistical evaluation of biomarkers as surrogate endpoints: a literature review.生物标志物作为替代终点的统计学评估:文献综述
Stat Med. 2006 Jan 30;25(2):183-203. doi: 10.1002/sim.2319.

引用本文的文献

1
Predicting Clinical Outcomes Using Molecular Biomarkers.使用分子生物标志物预测临床结果
Biomark Cancer. 2016 Jun 6;8:89-99. doi: 10.4137/BIC.S33380. eCollection 2016.